Abstract
About the Authors
Gillian Dudeck, PharmD, is an ambulatory cardiology clinical pharmacist at Geisinger Medical Center in Danville, Pennsylvania.
Heather Goetze, PharmD, TTS, is a clinical pharmacy specialist at Allegheny Health Network in Pittsburgh.
Brittany Nolton, PharmD, BCACP, is a senior health outcomes pharmacist at Highmark Health in Pittsburgh.
Luke Gormley, PharmD, BCCP, is an associate medical liaison at AstraZeneca.
Disclosures
At the time of writing, Gormley was a clinical pharmacy specialist at Allegheny Health Network in Pittsburgh. This project received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Objectives
The primary objective of this project was to determine the percentage of patients eligible for but not enrolled in Pennsylvania’s medication assistance programs, Pharmaceutical Assistance Contract for the Elderly (PACE) and PACE Needs Enhancement Tier (PACENET). Secondary objectives included quantifying the number of patients successfully enrolled, number of brand-name cardiovascular medications impacted by enrollment, and estimated cost saved by patients after enrollment in PACE/PACENET.
Project Design
This prospective quality improvement project evaluated patients followed by the Heart Care team at a large academic medical center in Pennsylvania for guideline-directed medical therapy (GDMT) optimization and affordability from October 1, 2024, to March 1, 2025.
Methods
Patients with Medicare Part D plans with orders for prespecified brand-name cardiovascular medications were screened for PACE/PACENET eligibility and provided with enrollment information during their admission. After discharge, eligible patients received a follow-up telephone call to confirm or assist with enrollment.
Results
A total of 100 patients were included in this project. After the initial screening, 19 patients were enrolled, and 43 patients did not qualify for PACE/PACENET. Thirty-eight patients were determined to be eligible but not enrolled, and, after further criteria-based screening, 27 patients remained eligible for PACE/PACENET enrollment. Over the course of the project,
3 patients were enrolled in PACENET, impacting their access to 5 brand-name cardiovascular medications and saving the patients an estimated combined total of $579.65 per month.
Conclusions
Pharmacists play a critical role in identifying patients with financial burdens and facilitating access to cost-assistance programs. Health systems can incorporate strategies to identify medication affordability issues and assist with enrollment in prescription assistance programs as part of the transitions-of-care process.
Introduction
According to the World Health Organization, ischemic heart disease and stroke were the first and third leading causes of death around the world in 2021, respectively.1 By the year 2030, cardiovascular disease (CVD) is expected to be the leading cause of death in patients 65 years and older.2 The prevalence of CVD in patients 60 to 79 years old is 75% in the United States, with age being one of the most important risk factors for both CVD and its associated high health care burden.2,3 The prevalence of atrial fibrillation is expected to nearly triple by the year 2050 as the population of adults 65 years and older in the US continues to rapidly grow.4 Heart failure has reached global pandemic status, with an estimated increase in prevalence by 2030 to 8.5% of individuals in the US aged 65 to 70 years.5,6
An analysis of Medicare beneficiaries by Zhang et al showed that improved adherence to cardiovascular medications following a myocardial infarction was associated with a reduction in heart disease–related readmission rates within 6 to 12 months of discharge.7 However, a survey conducted by AARP in 2024 found that 38% of adults 65 years and older eligible for Medicare had avoided filling a prescription because of its cost or knew someone who had.8 These data indicate a potential associated risk between decreasing medication affordability and increasing hospitalizations among the Medicare population.
Many CVD treatment guidelines recommend 1 or more high-cost brand-name medications as first-line therapy. Since 2019, direct-acting oral anticoagulants (DOACs) have been recommended over warfarin for the treatment of nonvalvular atrial fibrillation because of their lower rates of major bleeding and stroke.9 Though DOAC utilization has increased, cost remains a significant barrier for patients who cannot afford the 25-fold difference in price.10 In acute coronary syndromes, Brilinta (AstraZeneca; ticagrelor) is generally recommended over other P2Y12 inhibitors for its reduced risk of death from vascular causes, myocardial infarction, or stroke.11 On average, Medicare patients pay $67.24 out of pocket per month for Brilinta.12 As of 2023, the standard of care for heart failure treatment includes a sodium-glucose cotransporter 2 inhibitor (SGLT2i), regardless of ejection fraction, and an angiotensin receptor–neprilysin inhibitor (ARNI) for most ejection fractions.13,14 Guideline-directed medical therapy (GDMT) with an SGLT2i, ARNI, β-blocker (BB), and mineralocorticoid receptor antagonist (MRA) has the greatest evidence for reducing morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF).15 The 2-year mortality rate is 35% for patients with HFrEF who are not on GDMT.6 A 2022 review found the median out-of-pocket cost of GDMT for Medicare recipients was $2217 annually. Less-preferred medication regimens, including a BB, MRA, and either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, cost approximately $159 annually.15
The Pharmaceutical Assistance Contract for the Elderly (PACE) and PACE Needs Enhancement Tier (PACENET) programs help qualified Pennsylvania residents, including those with Medicare Part D coverage, reduce out-of-pocket prescription costs. Patients 65 years and older who meet the limited-income requirements are eligible to receive brand-name medications for up to $9 per month with PACE or $15 per month with PACENET.16 In 2022, the PACE Application Center reached out to 190,700 eligible Pennsylvanians, of whom only 8900 submitted applications.17 That same year, over 2.8 million Pennsylvania residents were enrolled in Medicare, accounting for more than 22% of the total state population.18
Pharmacists involved in transitions of care are well positioned to intervene on medication safety, efficacy, and affordability issues that arise. By augmenting traditional inpatient management strategies with a transitions-of-care pharmacist, health systems can realize cost savings associated with readmissions and improve patient outcomes. A time-and-motion cost analysis conducted within 2 large academic medical centers in the US found the estimated cost of pharmacists’ interventions was $101 per hospitalization. Compared with the typical cost of an adverse drug event in older adults ($1200 to $2500) and a hospital readmission (> $15,000), the average cost of a multicomponent quality improvement intervention aimed at preventing readmission is just $554.19,20 With this investment, hospitals can see a 7% to 14% reduction in emergency department visits or readmissions.20,21 A core element of pharmacist-mediated transitions of care is assessing and optimizing medication regimens not only to align with evidence-based recommendations but also to ensure financial feasibility.19 Despite medication affordability being a common pharmacist intervention, there are limited data available detailing the impact of pharmacist-led medication cost-savings initiatives.
The academic medical center’s Heart Care team is a comprehensive care team of nurse navigators, nurse practitioners, cardiac rehabilitation specialists, resource care assistants, quality coordinators, and a clinical pharmacist. The Heart Care team’s mission is to assist in transitions of care to optimize patient outcomes. The role of the clinical pharmacist on the Heart Care team is to identify transitions-of-care patients and recommend evidence-based pharmacotherapeutic regimens.
The center’s Pharmacist Standard of Care, which was implemented in September 2024, is as follows: